Cytoplasmic progestin-receptors in guinea pig brain: characteristics and relationship to the induction of sexual behavior.
The synthetic progestin, R 5020, was used to measure cytoplasmic progestin receptors in the brain and pituitary gland of ovariectomized guinea pigs. Progestin receptors with a dissociation constant of 0.1--0.3 nM were measured by gel filtration in all brain regions studied, pituitary gland and the uterus. The receptor is progestin-specific; biologically potent progestins compete well against [3H]R 5020 for binding, but androgens, glucocorticoids and estrogens do not. The concentration of the cytoplasmic progestin receptor in hypothalamus-preoptic area-septum and midbrain is decreased in vivo by behaviorally effective doses of progesterone. In the pituitary gland, hypothalamus, preoptic area-septum and midbrain, but not other brain regions, the concentration of progestin receptors increases after estradiol benzoate-priming. The increase in the concentration of cytoplasmic progestin receptors in hypothalamus-preoptic area-septum is dependent on the dose of estradiol benzoate injected. After a single injection of a dose of estradiol benzoate routinely used to facilitate the display of sexual receptivity (1.6 microgram estradiol benzoate/animal), the latency to an increase and subsequent decrease in cytoplasmic progestin receptors in the hypothalamus-preoptic area-septum correlates well with the previously reported time course for progesterone's facilitation of sexual receptivity after estradiol benzoate injection. The experiments are consistent with the notion that brain progestin receptors mediate at least some of the behavioral effects of progesterone.
D004092:20-alpha-Dihydroprogesterone / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000502:physiology; D002369:Castration; D003345:Corticosterone / Q000494:pharmacology; D003600:Cytosol / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D006168:Guinea Pigs; D009644:Norgestrel / Q000494:pharmacology; D009649:Norpregnadienes / Q000378:metabolism*; D011374:Progesterone / Q000494:pharmacology; D011397:Promegestone / Q000378:metabolism* / Q000494:pharmacology; D011980:Receptors, Progesterone / Q000187:drug effects / Q000502:physiology*; D012726:Sexual Behavior, Animal / Q000187:drug effects / Q000502:physiology*
D009649:Norpregnadienes; D011980:Receptors, Progesterone; D004092:20-alpha-Dihydroprogesterone; D009644:Norgestrel; D011374:Progesterone; D004958:Estradiol; D011397:Promegestone; D003345:Corticosterone